Consolidated Statements of Comprehensive Loss-Unaudited - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenues:
Net product revenue	$ 8,985	$ 8,672	$ 16,862	$ 15,412
Collaborative agreements	25	860	33	3,299
Royalties and other revenue	153	150	267	187
Total revenues	9,163	9,682	17,162	18,898
Operating expenses:
Cost of sales (including finite-lived intangible asset amortization)	728	1,327	1,296	1,880
Research and development, including stock-based compensation of $1,949, $1,903, $4,125 and $3,671, respectively	57,301	12,637	112,482	24,659
Selling, general and administrative expenses, included stock-based compensation of $2,309, $1,863, $4,565 and $3,506, respectively	14,113	14,263	28,801	28,373
Asset Impairment Charges	1,600	0	1,600	0
Total operating expenses	73,742	28,227	144,179	54,912
Loss from operations	(64,579)	(18,545)	(127,017)	(36,014)
Interest expense	(5,125)	(5,164)	(10,256)	(10,281)
Interest and other income, net	633	691	1,591	1,480
Net loss	$ (69,071)	$ (23,018)	$ (135,682)	$ (44,815)
Net loss per common share, Basic and Diluted	$ (0.65)	$ (0.22)	$ (1.27)	$ (0.42)
Shares used in computing net loss per common share, Basic and Diluted	107,073	106,272	106,804	106,164
Unrealized gain on investments	$ (548)	$ 53	$ 228	$ 98
Comprehensive loss	(69,619)	(22,965)	(135,454)	(44,717)
Stock-based compensation expense associated with research and development expense	1,949	1,903	4,125	3,671
Stock-based compensation expense associated with selling, general and administrative expense	$ 2,309	$ 1,863	$ 4,565	$ 3,506